Supadmi Woro, Izzah Qorni N, Suwantika Auliya A, Perwitasari Dyah A, Abdulah Rizky
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.
J Pharm Bioallied Sci. 2019 Dec;11(Suppl 4):S587-S593. doi: 10.4103/jpbs.JPBS_214_19. Epub 2019 Dec 30.
Dengue hemorrhagic fever (DHF) caused by the dengue virus is one of the high-prevalence diseases in tropical countries, such as Indonesia. It has been highlighted that high-prevalence diseases are strongly correlated with high-treatment costs. In particular, Yogyakarta has been reported as one of the provinces with a high prevalence of DHF. This study aimed to estimate the cost of illness because of DHF and to analyze the correlation between the use of drugs with its cost and length of stay, with total hospital administrative cost at one of the private hospitals in Yogyakarta. A cross-sectional study was applied in this study by collecting patients' medical record and financial data, such as demographic characteristic, medication, length of stay, and direct medical cost health-care perspective. The numbers of dengue patients were applied in this study by considering 87 patients and 143 patients with DHF in 2015 and 2016, respectively. Indirect medical costs were collected from a questionnaire by 20 respondents. Spearman's statistical test was used in this study to conduct the bivariate test. The average direct medical cost from the perspective of health care in 2015 and 2016 in DHF patients with Badan Penyelenggara Jaminan Sosial (BPJS) insurance and non-BPJS insurance was US$243.6; US$363.41 and US$368.13; US$427.03. The indirect medical costs showed that the highest percentage productivity loss was US$70.98-212.95. Correlation between the numbers of drug with drug cost was significant ( < 0.05) with correlation coefficient (value ) of 0.527 and 0.603. Correlation between lengths of stay with the cost of hospitalization was significant ( < 0.05) with correlation coefficient (value ) of 0.375 and 0.562. It can be concluded that DHF has a relatively high cost of illness both in direct and indirect costs.
由登革热病毒引起的登革出血热（DHF）是印度尼西亚等热带国家的高发性疾病之一。据强调，高发性疾病与高治疗成本密切相关。特别是，日惹已被报道为登革出血热高发病率的省份之一。本研究旨在估算登革出血热的疾病成本，并分析药物使用与其成本和住院时间之间的相关性，以及日惹一家私立医院的总医院行政成本。本研究采用横断面研究方法，收集患者的病历和财务数据，如人口统计学特征、用药情况、住院时间和直接医疗成本（从医疗保健角度）。本研究分别考虑了2015年的87例登革热患者和2016年的143例登革出血热患者。通过20名受访者的问卷调查收集间接医疗成本。本研究使用斯皮尔曼统计检验进行双变量检验。2015年和2016年，有社会医疗保险（BPJS）和无BPJS保险的登革出血热患者从医疗保健角度看的平均直接医疗成本分别为243.6美元、363.41美元和368.13美元、427.03美元。间接医疗成本显示，最高的生产率损失百分比为70.98 - 212.95美元。药物数量与药物成本之间的相关性显著（<0.05），相关系数（值）分别为0.527和0.603。住院时间与住院成本之间的相关性显著（<0.05），相关系数（值）分别为0.375和0.562。可以得出结论，登革出血热在直接和间接成本方面都有相对较高的疾病成本。
